Researchers have taken a critical step toward developing a non-invasive nuclear medicine technique that can predict the effectiveness of therapy for cancerous tumours, allowing for personalised, precision treatment.
The study is featured in the December isse of The Journal of Nuclear Medicine.
89Zr-immuno-PET is a noninvasive, whole-body imaging technique with the potential to predict the effectiveness of therapeutic antibodies (or their conjugates) in treating tumours.
This is a significant advance: currently, the only ways to measure this are through tissue sampling, which is invasive and noncomprehensive, or by measuring concentrations of monoclonal antibodies in blood samples.
“This study provides proof of concept that PET imaging with 89Zr-labeled antibodies can be used to assess physiological components of antibody biodistribution,” explains Yvonne Jauw, MD, at the Cancer Center Amsterdam, Amsterdam UMC in The Netherlands.
“This research enables us to apply molecular imaging as a noninvasive clinical tool to measure antibody concentrations in normal tissues.”
In this retrospective analysis of clinical 89Zr-immuno-PET studies, data from 128 PET scans were collected from Amsterdam UMC; CHU Lille in Lille, France; and Memorial Sloan Kettering Cancer Center in New York, New York.
The scans were of 36 patients and were done one to seven days after injection with the appropriate 89Zr-labeled antibodies for imaging their tumours.
Nonspecific uptake was defined as uptake measured in tissues without known target expression (normal tissue).
The results show that imaging with 89Zr-immuno-PET can be used to optimise detection of tumours throughout a patient’s body.
Nonspecific uptake of monoclonal antibodies in tissues without target expression can be quantified using 89Zr-immuno-PET at multiple time points.
These results form a crucial base for measurement of target engagement by therapeutic antibodies in a living person.
For future studies, a pilot phase, including at least three scans at one or more days after injection, is needed to assess nonspecific uptake as a function of time and to optimise study design for detection of target engagement and effectiveness against tumours.
The study has important implications for patients, as Jauw points out: “Knowledge of antibody distribution to normal tissues and tumours can be used to increase our understanding of which drugs will be effective and which drugs are likely to cause toxicity.”
In the future, this clinical tool could also be used in the selection of monoclonal antibodies during drug development, as well as the selection of patients who could benefit from a specific treatment.